A pilot qualitative study to explore stakeholder opinions regarding prescribing quality indicators by Martirosyan, L. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/107726
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
RESEARCH ARTICLE Open Access
A pilot qualitative study to explore stakeholder
opinions regarding prescribing quality indicators
Liana Martirosyan1*, Joekie Markhorst2, Petra Denig1, Flora M Haaijer-Ruskamp1 and Jozé Braspenning2
Abstract
Background: Information on prescribing quality of diabetes care is required by health care providers, insurance
companies, policy makers, and the public. Knowledge regarding the opinions and preferences of all involved parties
regarding prescribing quality information is important for effective use of prescribing quality indicators.
Methods: Between June and December 2009 we conducted semi structured interviews with 16 key-informants
representing eight different organizations in the Netherlands involved in healthcare quality measurement and
improvement. The interview guide included topics on participants’ opinions and preferences regarding existing
types of prescribing quality indicators in relation to their aim of using quality information. Content analysis methods
were used to process the resulting transcripts following the framework of predetermined themes.
Results: Findings from this qualitative study of stakeholder preferences showed that indicators focusing on
undertreatment are found important by all participants. Furthermore, health care providers and policy makers
valued prescribing safety indicators, insurance companies prioritized indicators focusing on prescribing costs, and
patients’ organization representatives valued indicators focusing on interpersonal side of prescribing.
Representatives of all stakeholders preferred positive formulation of the indicators to motivate health care providers
to participate in health improvement programs. A composite score was found to be most useful by all participants
as a starting point of prescribing quality assessment. Lack of information on reasons for deviating from guidelines
recommendations appeared to be the most important barrier for using prescribing quality indicators. According to
the health care providers, there are many legitimate reasons for not prescribing the recommended treatment and
these reasons are not always taken into account by external evaluators. The latter may cause mistrust of health care
providers towards external stakeholders and limit the use of PQI in external quality improvement programs.
Conclusion: Prescribing quality indicators are considered to be an important tool for assessing quality of provided
diabetes care by all participants, although the preferences for specific types of indicators may differ by stakeholder
depending on their user aim. Introduction of information systems to register the reasons for deviating from the
recommended drug treatment may contribute to a more widespread use of PQI for assessment of provided health
care quality to diabetic patents. This study identified the potential preferences regarding quality indicators for
diabetes care, and this could be used for development of questionnaires to conduct a survey among a larger group
of participants.
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Background
Insight into the quality care is demanded by healthcare
providers, payers, and patients. These different stake-
holders use quality information for different purposes
such as internal quality improvement, cost containment,
and accountability. There is general agreement that due
to varying aims of using quality information, the differ-
ent stakeholders have specific preferences for the type of
quality information [1-3]. However, not much is known
about their actual preferences. In this study, we explored
the opinions and preferences of different stakeholders
regarding prescribing quality indicators in diabetes care.
Appropriate drug prescribing has been recognized as
an important quality of care issue in the management of
chronic conditions, such as type 2 diabetes mellitus
(T2DM). Diabetes is a chronic disease with a dramatic-
ally increasing prevalence throughout the world [4]. Ap-
propriate pharmacological treatment of diabetes and
related risk factors helps to reduce complications in
patients with T2DM [5].
To measure quality of prescribing in T2DM, a large
number of prescribing quality indicators (PQI) has been
developed [6]. Among the existing PQI there are distinct
types of PQI that address different aspects of prescribing,
i.e. PQI focusing on undertreatment, safety, first choice
medication, and costs. The PQI focusing on undertreat-
ment look into prescription of medication in patients with
a specific diagnosis or elevated values of clinical measure-
ments. The safety PQI address prescription of medications
in those with contraindications or side effects. The first
choice PQI assess prescription of a medication within its
drug class based on the guideline recommendations, and
PQI focusing on costs assess prescription of the cheapest
medication within its drug class. Despite the increasing
number, the PQI for T2DM management are largely
underrepresented in national sets of quality measures that
are used for external accountability in different countries.
For example, the National Voluntary Consensus Standards
for Adult Diabetes Care includes two PQI focusing on
management of diabetic patients [7], and only these PQI
were included in the Health Employer Data Information
Set (HEDIS) of measures [8]. The Diabetes Quality Im-
provement Project, which was implemented in the United
States as a comprehensive set of national diabetes quality
measures, did not include any PQI for internal quality im-
provement or for accountability [9]. The PQI are also
underrepresented in the Quality and Outcome Framework
set of quality indicators in the United Kingdom with only
one PQI relevant for diabetes care [10]. The Australian
national set of diabetes indicators does not include any ex-
plicit PQI [11]. On the other hand, in some countries, for
example, the United Kingdom and Australia, there are sets
of internal quality indicators exclusively focusing on pre-
scribing issues [12,13]. In the Netherlands, a similar
situation exists with PQI mainly being used for internal
quality improvement and only a few used for accountabil-
ity purposes [14,15]. The reasons why PQI are not widely
used by different stakeholders, especially for external qual-
ity assessment, are not obvious. It is not clear if stake-
holders such as health insurance companies or policy
makers do not find the PQI useful for their work or if
there are obstacles in implementation of quality improve-
ment programs with the use of PQI.
Previous studies investigating the preferences for PQI
focused mostly on needs of healthcare providers (HCP).
It was found that PQI based on detailed patient clinical
information are preferred to those based on aggregated
data [16], and that physicians rank evidence-based PQI
higher than those based on costs [17]. However, there is
scarce knowledge regarding the types of PQI that are
found relevant by other stakeholders. Furthermore, little
is known about the preferred format of presenting the
scores of PQI. For instance, it is possible to focus either
on numbers of patients receiving appropriate care or on
patients receiving inappropriate care. Also, indicators
can represent one specific item of care or can average
several items into a composite score. The use of PQI
could be more effective if we had a better understanding
of ways to present quality information that are most
meaningful to the involved stakeholders.
The aim of the current pilot study was to facilitate the
future selection of prescribing quality indicators for
management of type 2 diabetes by conducting interviews
with the key representatives of several relevant organiza-
tions involved in development of such measures in the
Netherlands. We explored whether and why the PQI are
considered a relevant part of quality assessment of
T2DM care, and which types of PQI should be included
in quality improvement programs for diabetes according
to different key representatives. In addition, we wanted
to elicit the preferred way of receiving quality informa-
tion as well as the perceived barriers regarding PQI use.
Methods
Study population
The present study draws on 16 semi-structured inter-
views with professionals involved in quality of care
assessment using quality indicators. These participants
worked for eight organizations responsible for health-
care policy development and involved in quality meas-
urement or improvement in the Netherlands. The
participating organizations represented (1) patient
representatives, (2) healthcare providers, (3) payers, and
(4) the Ministry of health, welfare and sport of the
Netherlands (Table 1).
We have chosen to conduct in-depth interviews, as
not much is known about the reasons for choosing and
using different types of PQI by relevant stakeholders,
Martirosyan et al. BMC Health Services Research 2012, 12:191 Page 2 of 12
http://www.biomedcentral.com/1472-6963/12/191
e.g. insurance companies or health care professionals.
Considering the lack of information on this issue made
it impossible to define specific categories of potential
answers and to conduct a survey. We were interested in
specific reasons for using distinct types PQI, i.e. PQI fo-
cusing on undetreatment, safety, first choice drug and
costs, by different stakeholders, barriers for implementa-
tion of PQI in the daily practice and the future they see
for the PQI for their organization. In-depth interviews
were therefore considered relevant to answer the re-
search questions in this study.
Purposive sampling was used to identify the partici-
pants from each organization, i.e. senior staff members
who were engaged in quality of care measurement or
improvement using quality indicators within the
organization. We have contacted our respondents dir-
ectly or identified them through other employees of the
included organizations by asking them to suggest the se-
nior staff members whose tasks are most closely related
to quality assessment or improvement with use of qual-
ity indicators. For example, within the Ministry of
health, welfare and sport we have contacted the health
inspectorate, an organization within the ministry respon-
sible for the quality and safety of provided health care in
the Netherlands. For patient representatives, we have
selected the Federation of patients and consumers’ orga-
nizations, as this organization is dealing with patient
rights and preferences in the Netherlands in different
disease areas including diabetes. We did not aim to include
patients with diagnosis of T2DM the questions included in
the semi-structured guide required professional knowledge
regarding different types of prescribing quality indicators
and their use for quality assessment. For the relevant
sample of the health care providers, we have selected
professionals (diabetes nurses, primary care physicians,
specialists, and pharmacists) who were the active mem-
bers of several professional organizations involved in
health care quality improvement in the Netherlands
(Table 1). Another stakeholder, payers, was represented
by three different health insurance companies that are
operating in different geographical regions of the
country. All participants received a letter containing
information about the aim and methodology of the
study.
Under Dutch law, ethical approval is not required for
studies using face-to-face interviews. Therefore, this
study was exempted from approval of the medical ethics
committee.
Interview guide
A semi-structured guide was used that included open-
ended questions about aims of collecting and using qual-
ity information, and more specific questions related to
opinions about and preferences for different types of
existing PQI, the preferred way of receiving quality in-
formation, and factors limiting their use. The following
topics were covered in the interview guide: a) Current
usage and aims of using prescribing quality indicators; b)
Opinions regarding the relevance of including PQI on
assessment of quality of diabetes care; c) Opinions
regarding and prioritization of existing types of PQI,
i.e. focusing on undertreatment, safety, first drug choice,
Table 1 Participating stakeholders and organizations
Stakeholder Organization Positions of interviewed persons
Patient organization The Federation of Patients and Consumers’ Organizations Senior policy officer
Medical advisor
Health care providers Dutch Institute of Health Care Quality Improvement Senior advisor/diabetologist
Dutch College of General Practitioners Authors of national diabetes guidelines
for primary care/primary care physicians
Dutch Diabetes Federation Diabetologist
Diabetes nurse
Royal Association for the Advancement of Pharmacy Senior researcher/pharmacist
Scientific Institute of Dutch Pharmacists Senior manager/pharmacist
Community health care providers Primary care physician
Diabetes nurse
Payers Health insurance companies* Health program manager
Health care purchaser
Medical advisor
Policy makers Ministry of health, welfare and sport/Dutch Senior inspector
Health Care Inspectorate Primary health care inspector
*We have included three different insurance companies covering different geographical regions in the country.
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and costs; d) Opinions regarding formulation of the PQI
(positive versus negative score); e) Opinions regarding
aggregation level of the PQI; and f ) Perceived barriers
for implementation of PQI. After eliciting opinions
regarding existing types of PQI, on undertreatment, first
choice-drug, safety and costs, we have asked the parti-
cipants to choose the type(s) of PQI that were most
relevant for their work and the reasons for their
prioritization. The instrument was pilot-tested prior to
the data collection.
Data collection
Data collection was carried out between July-December
2009. The interviews were conducted face-to-face for 13
participants and by telephone for three participants who
preferred to be interviewed this way. Interviews lasted
on average 1.5 hours, ranging from one to two hours.
The face-to-face interviews were conducted by two
researchers; one was conducting the interviews and an-
other one was making notes. The interviewer asked open-
ended questions to reveal participants’ views and prefer-
ences, and then probed for clarification or to explore new
themes as they appeared. All interviews were recorded on
digital recorders with permission of participants. All parti-
cipants gave a written consent to participate in the inter-
view. To ensure the accuracy of our data we used several
techniques. First, the interviews were translated verbatim
independently by the two researchers present at the inter-
views. The transcripts were compared and disagreement
was resolved through discussion. Next, the accuracy of all
transcripts was checked against the original recordings by
an independent researcher. Finally, the transcripts of
interviews were sent back to the interviewees who were
asked to check their consistency and accuracy before
the analysis.
Analysis
The analysis of data began in parallel to data collection.
The semi-structured interview guide was only slightly
adjusted in the course of interviews, i.e. the sequence of
some of the questions has been adjusted to improve the
logical flow of the information, and we had the same
topics and questions covered in all interviews.
The transcripts of each of the interviews were analyzed
using a content analysis [18] according to a predeter-
mined framework. This framework was based on the
known knowledge regarding the use of PQI by different
stakeholders as described earlier in this paper. In this
framework, opinions of different stakeholders regarding
the use of PQI were divided into the following four main
themes: (1) relevance of PQI for measuring the quality
of provided diabetes care; (2) opinions and preferences
for specific types of PQI; (3) potential barriers for using
PQI; (4) preferred ways of receiving prescribing quality
information. Within these pre-defined themes, we iden-
tified parts of text that related to the same concepts.
Next, we coded data by giving descriptive code-names to
these concepts. Later, we grouped similar codes under
the larger, main categories. Finally, we re-organized our
data by stakeholder in order to identify differences and
similarities per stakeholder.
The transcripts of each interview were initially coded
by the first co-author with regular discussion of an
emerging framework for data coding with other co-
authors followed by the second co-author’s review of
coding. We used qualitative analysis software (ATLAS.ti
Win 6.1) to facilitate organization of data into codes,
categories and themes [19].
Results
Usage and aims of prescribing quality indicators by the
stakeholders
All participants with the exception of the representatives of
the patient organization used some sort of PQI for T2DM
management. Primary care physicians and diabetologists
use PQI for T2DM management for internal quality im-
provement initiatives such as peer review. The representa-
tives from the Dutch Health Inspectorate are primarily
interested in investigating and following up on problems
encountered in medical institutions. Therefore, they mainly
use outcome quality indicators to identify the healthcare
institutions that do not meet the minimal levels of prede-
fined standards of quality. Recently, however, they launched
a set of PQI for pharmacies to improve pharmaceutical
care. Pharmacists in the Netherlands are increasingly being
involved in pharmaceutical care and prescribing quality as-
sessment, and are encouraged to search for patients not re-
ceiving the optimal treatment and alert physicians. For
these purposes, they use various PQI for T2DM manage-
ment and report the scores of these indicators to the In-
spectorate. In addition, pharmacists report on PQI focusing
on costs of medication to health insurance companies.
Health insurance companies primarily collect PQI focusing
on costs to provide financial incentives to the HCP that
keep prescribing costs low. Finally, the patient organiza-
tions collect quality information to support patients when
making HCP choices, and to develop policies where
patients' preferences are taken into account. Currently, no
PQI are used by patient organizations.
Relevance of using PQI for assessing the quality of
provided diabetes care
PQI are an integral part of diabetes quality indicators set
Representatives of all included stakeholders stressed the
importance of combining PQI with other quality indica-
tors of diabetes care to obtain a comprehensive picture
of provided quality. It was noted that since diabetes is a
chronic disease, there is a large number of factors that
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determine the final outcome of the treatment, and it is
precisely the combination of all relevant processes that
defines quality of diabetes care.
“The most important is overall treatment of an
individual patient; therefore prescribing should be
always evaluated in combination with other processes
and outcomes of care.” Diabetes nurse
“The prescribing quality for diabetes is as important
as the eye or foot exam. All aspects of treatment
should be taken into consideration.” Medical advisor/
health insurance company
Some participants strongly argued against the use of
PQI alone without other quality indicators, as different
quality indicators of diabetes care are highly interrelated,
i.e. the physicians need to measure and register certain
clinical values in the records, so later they are able to
make decisions about the treatment choices.
“I think that PQI should be seen as an integral part of
quality of diabetes care and should never be
considered separately from other quality indicators.”
Senior researcher/Royal Association for the
Advancement of Pharmacy
“. . .The PQI are only important if combined with
other quality indicators. Total care is more important
than the prescribing patterns alone.” General practitioner
PQI reflect actions of healthcare providers
The HCPs noted that there is a lot of attention on qual-
ity indicators focusing on measurement and registration
of HbA1c and other risk factors. Prescribing indicators,
however, are more relevant as measures reflecting the
actions of healthcare providers in response to observing
elevated risk factors, as eventually most of diabetic
patients require pharmacotherapy.
“Measurements of the blood pressure or cholesterol
are process indicators. These process indicators are pre-
requisites for follow up actions.. Currently, a lot of atten-
tion is still being paid to this type of indicators [focusing
on registration of measurements] that are actually not
very important. It is more important to know what the
health care providers do after observing elevated values
of risk factors, and prescribing quality indicators play an
important role here.” General practitioner/Dutch College
of General Practitioners
PQI reflect scientific evidence
All participants believed that it is important to include
PQI in quality improvement programs, because PQI
usually reflect the evidence-based recommendations
from clinical guidelines. Moreover, the HCPs stated that
prescribing is the most evidence-based part of diabetes
treatment, as the other processes of care, i.e. registration
of clinical measurements, lifestyle modification or diet
are not as well researched in relation to patient out-
comes as prescribing.
“. . .the evidence of patient-targeted educational
programs in relation to clinical outcomes is lacking,
while prescribing is supported by harder evidence,
and it is a very important part of diabetes treatment.”
General practitioner/Dutch College of General
Practitioners
Opinions regarding and prioritization of existing types
of PQI
PQI focusing on undertreatment
PQI focusing on undertreatment were found essential by
representatives of all stakeholders (Table 2). A room for
improvement and reflection of guidelines were the most
frequently mentioned reasons for being interested in
these PQI. The HCP found these PQI very relevant for
their work, because undertreatment of diabetic patients
remains a major problem in a practice.
“I think that this type of information [information on
undertreatment] is really important, because clinical
inertia [initiation or intensification of therapy when
indicated] is a big problem in treatment of type 2
diabetic patients. A good example is statines that are
hugely underprescribed in patients with T2DM.”
Diabetolgist/Dutch Institute for Healthcare
Improvement
Participating pharmacists noted that they prioritize
these PQI, because it is easy to improve the scores of
PQI focusing on undertreatment due to a large number
of undertreated patients.
“It is quite easy to improve on this type of indicators,
and of course it is always nice for pharmacists to
dispense more medications.” Senior manager/
Scientific Institute of Dutch Pharmacists
Representatives from health insurance companies
mentioned that they find these PQI very important be-
cause they reflect the timeliness of the start and intensi-
fication of treatment, and because undertreatment
results in complications that add to the healthcare costs
in long run.
“When patients need certain treatment, they should
be able to receive that treatment. In the end, poor
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care is more costly.” Healthcare program manager/
health insurance company
The representatives of the Health Inspectorate and the
patient organization considered undertreatment of
patients to be equal to the “wrong treatment”, and noted
that patients who are in need of therapy have the right
to be prescribed the recommended treatment.
“We are very much interested in PQI focusing on
undertreatment, as it [undertreatment] can harm
patients on the long run.” Primary Healthcare
Inspector/The Healthcare Inspectorate
PQI focusing on safety
PQI focusing on safety were prioritized by the HCPs and
the key informants from the Inspectorate. The HCPs
mentioned that a large number of diabetic patients have
kidney function impairment, and such patients are at
higher risk of experiencing side effects from the pre-
scribed medication. Therefore, safety issues in diabetic
patients with kidney impairment are high on their
agenda. Besides, the HCP noted that the average diabetic
patient requires multiple drugs and has other conditions
besides diabetes that put him more prone to experien-
cing side effects. The HCP found safety PQI focusing on
drug-drug and drug-disease interactions to be very im-
portant for assessing quality of provided diabetes care.
“Safety is first, because I do not want to harm patients
with the medication. Using safety PQI that may
prevent potential harm is very important for internal
quality improvement.” General Practitioner/Dutch
College of General Practitioners
“That is very important; as I see a lot of problems in
patients with kidney disease, or patients with swollen
ankles who get NSAIDs [non steroid anti-inflammatory
drugs] in high doses, and the kidney function collapses
because of that. I think interactions between different
[drug] classes are very important.” Diabetologist/Dutch
Institute of Healthcare Improvement
Pharmacists prioritized the PQI focusing on safety, as
they felt that they have the best knowledge on safety of
medication and, therefore, they have the capacity to have
a direct impact on improvement of patient’s safety in re-
lation to prescribed medication.
The representatives from the Inspectorate prioritized PQI
focusing on safety, because pharmacotherapy involves many
errors and suboptimal decisions, and patients will directly
benefit from the improvement in prescribing safety. In
addition, it was noted that safety of provided healthcare is
one of the most important criteria for the Healthcare
Inspectorate.
The participants from health insurance companies felt
that safety of prescribed medication should remain a pro-
fessional area to be monitored and improved internally. Al-
though they accepted the importance of safety PQI for
diabetes care, in their opinion, judgments on these indica-
tors require professional knowledge and skills they lack.
“It is important that insurance companies do not take
the place of healthcare providers and do not interfere
too much in prescribing process. I believe that
professionals are perfectly able to improve the safety
of prescribing themselves.” Healthcare purchaser/
Health insurance company
PQI focusing on first choice drug
The value of PQI focusing on the first choice drug as seen
by the key informants representing different stakeholders
was that they usually reflect guideline recommendations
and include a safety component. However, no interviewed
key informant found these PQI very relevant for their own
aims (Table 2). The health insurance representatives re-
ferred to these PQI as being only important in situations
when the first choice drug recommendations implied pre-
scription of cheaper medication. The representatives from
the Inspectorate mentioned that although these PQI usually
have good face validity, they do not always reflect prescrib-
ing quality. In particular, they noted that a high grade of
evidence is not always available to guide an evidence-based
drug choice, and in such situations the final drug choice
needs to be made by physicians. The HCPs had a similar
opinion about the PQI focusing on the first choice drug.
One participant argued that these PQI might be used for
internal purposes and never for external accountability.
The HCP argued that the first choice drug recommenda-
tions available in clinical guidelines cannot be applicable to
Table 2 Potential relevance of existing types of PQI for different stakeholders
Stakeholder Undertreatment Safety First choice drug Cost Communication
Patient organization ✓ ✓
Health care providers ✓ ✓
Payers ✓ ✓
Policy makers ✓ ✓
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all patients, as there will be always some patients that ex-
perience side effects, have contraindications, or refuse the
recommended medications, making these PQI very sensi-
tive to patient case-mix.
Another limitation of these PQI mentioned by the
representatives of the Inspectorate and the HCPs was
the dynamic nature of the evidence supporting first
choice drug recommendations. These participants noted
that the recommendation in guidelines can change, be-
cause of emerging evidence suggesting another first
choice drug.
“Fifteen years ago, a professional was considered
incompetent if he used it [metformin], as there were
too many side effects, whereas now it has become a
first-choice medication, which, of course, may change
again.” Senior Inspector/The Healthcare Inspectorate
In addition, pharmacists mentioned that information
on first choice drugs is not so crucial, as it often refers
to the choice from two drugs that can both be quite
good, and therefore, the difference is not as big as be-
tween safe and unsafe therapy.
PQI focusing on cost
PQI focusing on costs related to prescribing were recog-
nized as being relevant for the healthcare system by all
participants but they were prioritized only by the repre-
sentatives of health insurance companies. Key infor-
mants from other stakeholder organizations, while
accepting the importance of reducing costs attributed to
prescribing, felt that it is not their responsibility to con-
trol costs and mentioned that costs should not be the
main factor in the prescribing process. The participants
from the patient organization believed that costs do not
have a relation to quality, since quality means meeting
the needs of an individual patient without considering
costs. Similarly, representatives of the Inspectorate noted
that PQI focusing on costs are hardly interesting for
them as these PQI do not reflect quality of provided
care.
“Costs and quality go together, but costs are not a
priority for the Inspectorate. For instance, if we know
that a certain medication is more effective than
another, less expensive medication, we prefer the
more effective medication in spite of the higher costs.
Indicators relating to costs are hardly interesting.”
Senior Inspector/The Healthcare Inspectorate
In general, all HCPs including pharmacists mentioned
that is not their priority to know if the cheapest medica-
tion has been prescribed. However, pharmacists men-
tioned that they do collect and report on PQI focusing
on costs, as this is requested by health insurance com-
panies. All stakeholders that did not prioritize PQI fo-
cusing on costs agreed that prescribing a cheaper
medication is only relevant in a situation when several
drugs with similar effectiveness are available.
PQI focusing on communication between HCP and patients
Representatives of the patient organization noted that al-
though there will always be patients who would like to
know the very detail about provided quality of care, for an
average patient it is difficult to judge the quality of care
with the existing PQI. In addition to the PQI focusing on
undertreatment, they prioritized a different type of PQI
that would reflect effective communication between HCPs
and patients regarding the prescribed medication. The
aspects considered as important were related to patients’
participation in the treatment process, self-management,
patients’ empowerment and motivation to comply with
the prescribed treatment, and provision of sufficient infor-
mation about prescribed medication in an acceptable and
understandable way.
“It is important to measure whether the [treatment]
decisions have been shared with patients, for instance
when introducing insulin treatment. . . Doctors should
motivate patients to comply with the therapy and to
try achieving the improved health status”. Senior
policy officer/Federation of Patients and Consumer
Organisations in the Netherlands
“The HCP should provide information about the
prescribed medication, for example common side-
effects to be expected, etc. And most importantly,
patients should believe in the medication prescribed
by a doctor.” Medical advisor/Federation of Patients
and Consumer Organisations in the Netherlands
Potential barriers for use of PQI
Reasons for deviating from the recommended treatment
The most frequently mentioned barrier for implement-
ing PQI was the concern that reasons for not prescribing
the recommended medication are ignored. The strongest
opinions were expressed by the HCPs, who noted that
many PQI are very sensitive to patient case-mix. Several
patients may encounter side-effects to the recommended
drugs, have contraindications, or simply refuse certain
types of medication due to, for example, negative experi-
ences in the past or influence of the media. There was a
general concern raised by the HCPs that external bodies
expect very high scores on indicators reflecting guideline
recommendations, and that the external evaluators may
not take into account all the legitimate reasons for not
prescribing a recommended treatment to certain patients.
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“Those things [side effects, contraindications and
patient refusals] are part of the equation and were
never understood by the government, insurance or
whatever. They say: “Oh, your score on prescription
of metformin is only 80%. That is very bad, it should
be 100%”. . . Ok, it is right it should be as high as
possible, but there can be very good reasons not to
prescribe the recommended treatment and that holds
true for many other prescribing quality indicators”.
Diabetologist/Dutch Institute for Healthcare
Improvement
The representatives of the Inspectorate and insurance
companies, however, did recognize that there might be
many legitimate reasons for deviating from the recom-
mended treatment. They mentioned that usually they do
not have insight to reasons for deviations, and knowing
this information would be very helpful for fair prescrib-
ing quality assessment.
Prescribing is a professional area
Representatives of insurance companies and the Inspect-
orate mentioned that for some specific types of PQI,
such as focusing on safety, one would need sufficient
professional knowledge to be able to judge the scores of
the indicators. It was mentioned that lack of such know-
ledge could be solved by setting up an expert panel.
According to the representatives of the Inspectorate, the
main reason why the information on PQI is not yet col-
lected from medical practices is a traditional belief that
prescribing is a professional domain in which the Health
inspectorate should not interfere unless obvious pro-
blems are encountered. The majority of the HCPs sup-
ported this view, as they believed that they are capable
of improving prescribing quality themselves by conduct-
ing internal audits and peer-review without external
interference.
“Measuring the quality of prescribing is new and
tricky for the Inspectorate. Some health inspectors
believe that prescribing is a professional domain in
which they should not interfere as they do not have
sufficient knowledge. It is, of course, possible to
organize an expert panel, but still the most important
point is whether or not prescribing should remain the
responsibility of the professionals. “Senior Inspector/
The Healthcare Inspectorate
“Doctors will not trust external evaluators for
prescribing quality assessment. Cost control is more
or less accepted, but quality assessment is not. We are
capable of improving quality ourselves without
interference of the Inspectorate or other external
bodies.” Community primary care physician
Operational feasibility
Although all participants agreed that currently avail-
able health records have the potential to provide infor-
mation on the most important prescribing quality
issues, operational feasibility was a frequently men-
tioned barrier to the actual use of PQI. In particular,
many mentioned that the feasibility of calculating
safety PQI is hampered, as this type of PQI require
additional clinical information, such as kidney func-
tion, co-medication, etc. This type of information is
not always available or easily retrievable from the
registration systems. This was a particularly important
issue for pharmacists. They believed to have the best
knowledge related to the medication safety issues, but
their involvement in prescribing quality improvement
was limited by the lack of sufficient patient clinical
data in the pharmacy registries.
“Prescription of certain medications in patients with
impaired kidney and liver function requires a special at-
tention, and pharmacists can be helpful in monitoring
this. However, pharmacists normally do not have an ac-
cess to such clinical information.” Senior researcher/
Royal Association for the Advancement of Pharmacy
Another important piece of information that in par-
ticular the HCPs and representatives of the patient
organization felt was lacking, was the documentation of
patient preferences for treatment choices, and socio-
economic factors that might influence patient prefer-
ences. The HCPs stressed the relevance of developing a
registration system where this type of information could
be entered in a systematic way, so it could assist
shared-decision making and taking into account patient
preferences.
Finally, the HCP mentioned that the numbers of PQI
developed for different clinical areas is growing mark-
edly, and there is a great time burden for them to deal
with such a large number of PQI. The same problem
was identified by the key informants from the Inspect-
orate, who mentioned that a large number of existing
indicators related to quality of prescribing makes the
choice of the most relevant PQI difficult.
Preferred ways of receiving the prescribing quality
information
Formulation of scores
A positive formulation of PQI scores was preferred by
most participants and in particular by the HCPs. All
HCPs mentioned that it is always better to start from
the figures that focus on numbers of patients who are
well treated, and only as a next step to discuss areas that
need improvement. Starting with negative figures was
thought as creating “a blaming culture” that can
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discourage and demotivate the HCPs from participation
in quality improvement programs or from providing
transparent data on quality.
“Try to be positive . . . What would be the incentive
for those who perform worse than the others? If you
put good guys in front and bad gays in the back, you
focus on the bad ones. . .Negative formulation creates
chaos and negative attitude.” Diabetologist/Dutch
Institute for Healthcare improvement
Key informants from insurance companies were well
aware of this fact, and preferred using positive figures to
improve the chances of making successful contracts with
HCPs.
“Positive formulation is important for creating a posi-
tive and encouraging atmosphere in the communication
process with the health care professionals. If you go to
the professionals and start the discussion with present-
ing figures that represent a good performance, this has a
stimulating effect.” Healthcare program manager/Health
insurance company
Aggregation level
When asked about preferences for aggregating PQI, all
participants mentioned that both “composite” and in-
dividual scores are useful. The HCPs preferred a “fold
out” system for internal quality assessment, where first
a composite score, i.e. an average of all PQI is used to
get a comprehensive overview, and next, it is folded
out to the individual PQI level to identify potential
areas for improvement. For external reporting, the
HCPs preferred using only a composite score. The
main underlying reason was the fear that external sta-
keholders may misinterpret the scores on individual
PQI because they may fail to acknowledge the possible
legitimate reasons for not prescribing the recom-
mended treatment to certain patients. All external sta-
keholders, however, preferred to be informed on both
aggregated and individual indicator level using a “fold
out” system. The use of composite scores was consid-
ered to be convenient by providing a quick overview
and eliminating the necessity of dealing with too many
quality indicators. Despite this, the composite score
was never considered informative enough. Information
on an individual PQI level would be desired eventually,
since only individual PQI scores ensure transparency
of the provided care and identify areas that require
special attention. Several participants mentioned that
composite scores should ideally aggregate only indica-
tors focusing on a similar topic, for example, safety or
undertreatment.
Discussion
Our study showed that all participants representing differ-
ent stakeholders thought that PQI are reflecting an im-
portant part of the treatment process of T2DM patients
and that PQI should be included in the T2DM quality im-
provement programs. All stakeholders found PQI focusing
on undertreatment to be very relevant for their own user
aims. In addition, the interviewed HCPs and the Inspect-
orate key informants prioritized PQI focusing on safety.
No participants found PQI focusing on the first choice
drug important for their aims. For the remainder, the par-
ticipants representing different stakeholders had differing
priorities for the types of PQI. Health insurance compan-
ies prioritized PQI focusing on costs, and the patient
organization valued quality indicators that would reflect
effective communication between patients and HCPs. Im-
portant barriers for using PQI were concerns that legitim-
ate reasons for not prescribing the recommended
treatment are overlooked, and relevant clinical informa-
tion is not always available for adequate prescribing qual-
ity assessment. As for the preferred way of presenting
scores of the PQI, we found that a positive formulation of
indicators is very important for encouraging the HCPs to
participate in prescribing quality improvement programs.
A composite score averaging several PQI was considered a
convenient way to start the process of prescribing quality
assessment by all participants, but scores on individual
PQI were always preferred to inform quality improvement
initiatives.
PQI are important tools for assessing quality of diabetes
care
We found that all participants stressed the importance of
including PQI for assessment of diabetes care. The rea-
sons brought forward by different stakeholders’ key infor-
mants included the relatively high level of evidence
available for PQI compared to other quality indicators,
and prescribing being a vital component of T2DM
management. Although carefully managing diet, exer-
cising, and self-monitoring contributes to improved
health outcomes in diabetic patients [20,21], for the ma-
jority of patients these interventions alone are not usu-
ally sufficient. To avoid or minimize chronic diabetic
complications, some sort of pharmacological treatment
will then be necessary because of progressing nature of
the disease [22].
Furthermore, there is an increasing interest from the
Healthcare Inspectorate in receiving information on qual-
ity and safety of medication use in the Netherlands. The
recent endorsement of prescribing indicators to be used
by pharmacies in the country, confirms this trend. Simi-
larly, the National Quality Forum in the United States
acknowledged that there are too few measures available to
improve the quality and safety of medication use and
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management, and endorsed 18 prescribing quality mea-
sures as a starting point. These measures focus on man-
aging over-the-counter and prescription medication
related to several conditions including diabetes [23].
Our results indicate that PQI focusing on undertreat-
ment can be included in a uniform set of quality indicators
to be used by all stakeholders. For the rest, the stake-
holders had differing preferences specific to their user
aims, and should used customized sets of PQI to reflect
their own interests and priority areas. We have found that
PQI focusing on costs were not interesting for the HCPs,
and this is consistent with findings from other studies
[17,24,25]. In the past, PQI on costs have been a part of
internal quality improvement programs [26-28]. Auditing
such information on prescribing appears to be less rele-
vant for HCP nowadays, probably because health insur-
ance companies now use different (reimbursement)
strategies to control the prescribing costs.
Preferences of stakeholders regarding PQI
The PQI focusing on first choice drugs were not priori-
tized by any stakeholder representative. The first drug
choice recommendations are an important component
of many clinical guidelines. However, PQI reflecting
these recommendations are more likely to be affected by
patient case-mix and the changing evidence base. In
comparison with the PQI that focus on undertreatment
and refer to prescribing of any drug from a certain class,
the PQI focusing on first choice drug look at prescribing
of a specific drug within a class. Therefore, it is more
likely that the scores of such PQI are lowered due to
some patients experiencing side effects or having contra-
indications to this specific drug. In addition, the chan-
ging nature of evidence supporting the PQI focusing on
first drug recommendations hampers comparisons of
prescribing quality scores over time.
Representatives of the patient organization and the
interviewed HCPs identified an existing gap regarding
information on interpersonal side of prescribing quality,
i.e. shared decision making and respect for patients’
preferences regarding the treatment options. Previous
research has shown that patients value effective com-
munication between HCP and patients in addition to
technical measures of quality [29]. Although reliable
measures for assessing patients’ experiences and per-
spective do exist, they are not widely incorporated into
quality assessment [30]. Knowing patients’ experiences
with their HCP is important, as there is evidence show-
ing the link between positive attitudes of patients to-
wards their HCP and improved patient outcomes [31].
To facilitate patients’ involvement in the treatment
process, it is important to systematically register patient-
related information, such as preferences for and experi-
ences with (drug) treatment, in the medical records.
Having such information may not only contribute to
improved communication between HCPs and patients but
will also provide the source for obtaining the type of qual-
ity information that patients value most.
The stakeholders’representatives agreed that PQI
should be positively formulated to create an encouraging
environment, which is considered very important for
participation of HCP in quality improvement programs
in general. For the preferred aggregation level, we have
found a discrepancy between HCPs and external stake-
holders. The HCPs were reluctant to share the prescrib-
ing quality data on individual PQI level because of
mistrust to the external evaluators. This is in line with
other studies showing the unwillingness of physicians to
share the quality data with the “general public” [32]. The
results of our study suggest that allowing legitimate
deviations from the recommended treatment might help
to minimize this tendency.
Potential barriers for use of PQI
We found that the lack of information on reasons why
the HCPs do not comply with the drug treatment
recommendations is a major barrier for effective use of
PQI for all stakeholders. This finding echoes the results
from other studies showing that adjustment to patients’
case-mix is a concern for physicians when publishing
quality information [33,34]. Such concerns from the
HCPs’ side are not unsubstantiated, as it has been shown
that for a prominent proportion of patients in clinical
practice there are legitimate reasons for not prescribing
the recommended treatment [35,36].
According to the Donabedian’s Triad Model of health-
care quality assessment [37], prescribing indicators are
typical process indicators as they refer to the treatment
of patients. In general, process indicators are considered
to be less affected by clinical characteristics of patients
compared to the outcome indicators [38]. That is particu-
larly true for process indicators that show percentages of
patients in whom certain laboratory measurements have
been conducted, or who have received a foot or eye exam.
With regard to sensitivity to patient case-mix, however,
PQI may behave more like outcome indicators. Presence
of comorbidities, patients’ age, co-prescribed medications,
contraindications, and possible side effects can all be rele-
vant for the prescribing process, and subsequently the
scores of PQI. Therefore, use of PQI requires the same
caution with regard to patient characteristics as outcome
indicators.
Limitations
There are some limitations to this study. We included the
most relevant organizations in the Netherlands that partici-
pate in health care quality measurement and improvement,
and within these organizations we recruited the employees
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whose tasks were most closely related to quality-of-
healthcare assessment or improvement. However, the opi-
nions of stakeholders elicited in this study may not neces-
sarily be representative for opinions of similar stakeholders
in other countries. In addition, we did not involve patients
with diagnosis of T2DM, as the topics covered during the
interviews required professional knowledge related to qual-
ity of prescribed medication and quality of care measure-
ment using quality indicators.
Suggestions for future research
A further larger quantitative study of stakeholders’ prefer-
ences regarding prescribing quality indicators would give
fuller and more generalisable results. Such a study of sta-
keholders' preferences, with higher participant numbers,
could also explore the factors that could optimize the use
of prescribing quality indicators, in particular for external
use.
In further studies, the actual patients with diagnosis of
type 2 diabetes could be included to better reflect on the
need and preferences of such patients regarding pre-
scribing quality issues.
Conclusions
Prescribing quality indicators, especially those focusing on
undertreatment, might be relevant for all stakeholders, and
therefore, could constitute a basis for selection of a uniform
set of quality indicators of diabetes care. The specific prefer-
ences of different stakeholders need to be studied in larger
groups of participants to reflect each stakeholders view.
This study suggests that limited use of PQI in external
quality improvement programs might be explained by the
fact that the score of PQI are influenced by the side effects,
contraindications and patient preferences for drug choice,
and these are not systematically taken into account at the
moment. Development of information systems for docu-
menting the reasons for deviations from the recommended
treatment and patient preferences could contribute to a
more widespread use of PQI for different aims.
Our study provides an important insight and a number
of domains that could be used for development of ques-
tionnaires and conducting surveys to select the prescrib-
ing quality indicator’s that are relevant for each of the
stakeholders including the ways to optimize their use in
daily practice.
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